The Medicines Company Company Profile (NASDAQ:MDCO)

About The Medicines Company (NASDAQ:MDCO)

The Medicines Company logoThe Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:MDCO
  • CUSIP: 58468810
  • Web: www.themedicinescompany.com
Capitalization:
  • Market Cap: $2.91 billion
  • Outstanding Shares: 71,072,000
Average Prices:
  • 50 Day Moving Avg: $49.14
  • 200 Day Moving Avg: $43.56
  • 52 Week Range: $30.80 - $55.95
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.89
  • P/E Growth: -0.12
Sales & Book Value:
  • Annual Revenue: $141.74 million
  • Price / Sales: 20.53
  • Book Value: $7.26 per share
  • Price / Book: 5.64
Profitability:
  • EBIDTA: ($306,000,000.00)
  • Net Margins: -96.44%
  • Return on Equity: -35.07%
  • Return on Assets: -14.80%
Debt:
  • Debt-to-Equity Ratio: 0.81%
  • Current Ratio: 3.46%
  • Quick Ratio: 3.12%
Misc:
  • Average Volume: 1.80 million shs.
  • Beta: 0.5
  • Short Ratio: 7.1
 

Frequently Asked Questions for The Medicines Company (NASDAQ:MDCO)

What is The Medicines Company's stock symbol?

The Medicines Company trades on the NASDAQ under the ticker symbol "MDCO."

How were The Medicines Company's earnings last quarter?

The Medicines Company (NASDAQ:MDCO) announced its quarterly earnings data on Wednesday, April, 26th. The company reported ($1.44) EPS for the quarter, missing the Zacks' consensus estimate of ($1.13) by $0.31. The business earned $24.20 million during the quarter, compared to analysts' expectations of $37.76 million. The Medicines Company had a negative net margin of 96.44% and a negative return on equity of 35.07%. The Medicines Company's revenue for the quarter was down 51.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.03) EPS. View The Medicines Company's Earnings History.

Where is The Medicines Company's stock going? Where will The Medicines Company's stock price be in 2017?

12 brokers have issued twelve-month price objectives for The Medicines Company's shares. Their forecasts range from $50.00 to $65.00. On average, they anticipate The Medicines Company's stock price to reach $56.11 in the next year. View Analyst Ratings for The Medicines Company.

What are analysts saying about The Medicines Company stock?

Here are some recent quotes from research analysts about The Medicines Company stock:

  • 1. Jefferies Group LLC analysts commented, " ACC (Mar 17-19) will be a key meeting for inclisiran, where MDCO will detail full 6-mo data for ORION-1 and AMGN will present the FOURIER data. Data from the latter should help guide PIII development for inclisiran, for which MDCO continues to seek a partner. On positive FOURIER results, we lower our risk-discount on inclisiran and our PT increases to $62 (v. $49 prev)." (3/1/2017)
  • 2. According to Zacks Investment Research, "The Medicines Co. has two potential blockbusters, Inclisiran and Carbavance, in different stages of development. Moreover, divestment of non-core assets to drive shareholder value is encouraging. We are also encouraged by the company’s acquisitions and in-licensing agreements to grow its pipeline. Moreover, the company’s shares have outperformed the Zacks classified Medical-Biomedical/Genetics industry in last one year. However the company is facing generic competition for its flagship product, Angiomax. With Angiomax sales eroding due to the presence of generics, the company’s ability to successfully develop and bring new products to market is important for future growth and any regulatory setbacks would weigh heavily on the stock. Estimates have been stable lately ahead of the company’s Q4 earnings release. The company has positive record of earnings surprises in recent quarters." (1/10/2017)

Are investors shorting The Medicines Company?

The Medicines Company saw a increase in short interest in April. As of April 13th, there was short interest totalling 16,083,668 shares, an increase of 3.6% from the March 31st total of 15,528,979 shares. Based on an average trading volume of 1,522,570 shares, the short-interest ratio is currently 10.6 days.

Who are some of The Medicines Company's key competitors?

Who owns The Medicines Company stock?

The Medicines Company's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.16%), Vanguard Group Inc. (8.62%), BOXER CAPITAL, LLC (8.00%), Aviva Holdings Ltd. (5.39%), Iridian Asset Management LLC CT (4.28%) and PARTNER FUND MANAGEMENT, L.P. (3.60%). Company insiders that own The Medicines Company stock include Armin M Kessler, Christopher T Cox, Clive Meanwell, Elizabeth H S Wyatt, Fredric N Eshelman, Glenn Sblendorio, Hiroaki Shigeta, Melvin K Spigelman, Robert G Savage, William Bernard O'connor and William Crouse. View Institutional Ownership Trends for The Medicines Company.

Who sold The Medicines Company stock? Who is selling The Medicines Company stock?

The Medicines Company's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Broadfin Capital LLC, Ashford Capital Management Inc., Nationwide Fund Advisors, Signpost Capital Advisors LP, Alliancebernstein L.P., Teachers Retirement System of The State of Kentucky and SG Americas Securities LLC. Company insiders that have sold The Medicines Company stock in the last year include Clive Meanwell, Hiroaki Shigeta, Melvin K Spigelman and William Bernard O'connor. View Insider Buying and Selling for The Medicines Company.

Who bought The Medicines Company stock? Who is buying The Medicines Company stock?

The Medicines Company's stock was bought by a variety of institutional investors in the last quarter, including Aviva Holdings Ltd., Iridian Asset Management LLC CT, Blue Ridge Capital L.L.C., Frontier Capital Management Co. LLC, Vanguard Group Inc., Westfield Capital Management Co. LP, Elk Creek Partners LLC and Ameriprise Financial Inc.. Company insiders that have bought The Medicines Company stock in the last two years include Christopher T Cox and Fredric N Eshelman. View Insider Buying and Selling for The Medicines Company.

How do I buy The Medicines Company stock?

Shares of The Medicines Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of The Medicines Company stock cost?

One share of The Medicines Company stock can currently be purchased for approximately $40.95.

Analyst Ratings

Consensus Ratings for The Medicines Company (NASDAQ:MDCO) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 9 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $56.11 (37.02% upside)

Analysts' Ratings History for The Medicines Company (NASDAQ:MDCO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/23/2017CIBCInitiated Coverage$50.00MediumView Rating Details
5/22/2017Oppenheimer Holdings Inc.Initiated CoverageMarket Perform$50.00LowView Rating Details
5/20/2017ValuEngineDowngradeSell -> Strong SellHighView Rating Details
4/19/2017Cowen and CompanyBoost Price TargetOutperform$39.00 -> $61.00LowView Rating Details
4/12/2017Jefferies Group LLCReiterated RatingBuy$62.00LowView Rating Details
3/20/2017HC WainwrightReiterated RatingBuy$60.00HighView Rating Details
3/18/2017JPMorgan Chase & Co.Reiterated RatingBuyHighView Rating Details
3/1/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
1/8/2017Chardan CapitalReiterated RatingBuy$65.00N/AView Rating Details
11/18/2016GuggenheimReiterated RatingBuyN/AView Rating Details
11/8/2016Leerink SwannReiterated RatingOutperform$53.00 -> $50.00N/AView Rating Details
8/2/2016Citigroup IncReiterated RatingHoldN/AView Rating Details
7/12/2016Bank of America CorpReiterated RatingBuyN/AView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$28.00 -> $31.00N/AView Rating Details
7/6/2015MizuhoUpgradeNeutral -> Buy$28.00 -> $41.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for The Medicines Company (NASDAQ:MDCO)
Earnings by Quarter for The Medicines Company (NASDAQ:MDCO)
Earnings History by Quarter for The Medicines Company (NASDAQ:MDCO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017Q1 2017($1.13)($1.44)$37.76 million$24.20 millionViewN/AView Earnings Details
2/28/2017Q416($1.43)($1.29)$26.91 million$25.20 millionViewListenView Earnings Details
10/26/2016Q316($1.38)($0.64)$37.26 million$37.60 millionViewListenView Earnings Details
7/27/2016Q216($1.16)($0.62)$41.93 million$54.70 millionViewListenView Earnings Details
5/9/2016Q116($0.89)($1.03)$48.96 million$50.30 millionViewListenView Earnings Details
2/17/2016Q415($1.54)($0.88)$64.11 million$67.20 millionViewN/AView Earnings Details
11/3/2015Q315($0.88)($0.90)$68.58 million$72.70 millionViewListenView Earnings Details
7/29/2015Q215($0.20)($0.74)$122.58 million$90.50 millionViewListenView Earnings Details
5/5/2015Q115($0.68)($0.02)$138.78 million$126.50 millionViewListenView Earnings Details
2/18/2015Q414($0.84)$0.11$188.55 million$191.00 millionViewListenView Earnings Details
10/22/2014Q314($0.10)$0.10$188.30 million$172.40 millionViewListenView Earnings Details
7/23/2014Q214($0.07)$0.22$183.75 million$183.80 millionViewListenView Earnings Details
4/23/2014Q114($0.13)$0.22$175.60 million$177.20 millionViewListenView Earnings Details
2/19/2014Q413$0.11$0.26$182.60 million$185.00 millionViewListenView Earnings Details
10/23/2013Q313$0.24$0.47$173.86 million$173.45 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.33$0.50$168.70 million$172.00 millionViewListenView Earnings Details
4/24/2013Q1 2013($0.26)$0.31$152.63 million$155.80 millionViewListenView Earnings Details
2/20/2013Q4 2012$0.28$0.38$146.09 million$159.50 millionViewListenView Earnings Details
10/24/2012$0.39$0.40ViewN/AView Earnings Details
7/25/2012$0.22$0.46ViewN/AView Earnings Details
4/25/2012$0.14$0.27ViewN/AView Earnings Details
2/22/2012$0.24$0.52ViewN/AView Earnings Details
10/26/2011$0.20$0.17ViewN/AView Earnings Details
7/27/2011$0.31$0.21ViewN/AView Earnings Details
4/27/2011$0.40$0.45ViewN/AView Earnings Details
2/16/2011$0.24$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for The Medicines Company (NASDAQ:MDCO)
2017 EPS Consensus Estimate: ($5.09)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.36)($1.06)($1.21)
Q2 20173($1.40)($1.10)($1.23)
Q3 20172($1.66)($1.17)($1.42)
Q4 20172($1.36)($1.11)($1.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for The Medicines Company (NASDAQ:MDCO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for The Medicines Company (NASDAQ:MDCO)
Insider Ownership Percentage: 7.90%
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Institutional Ownership by Quarter for The Medicines Company (NASDAQ:MDCO)
Insider Trades by Quarter for The Medicines Company (NASDAQ:MDCO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017William Bernard O'connorCFOSell25,833$46.20$1,193,484.60View SEC Filing  
12/8/2016Christopher T CoxEVPBuy105,500$33.20$3,502,600.00View SEC Filing  
12/8/2016Fredric N EshelmanDirectorBuy621,720$33.77$20,995,484.40View SEC Filing  
9/21/2016Clive MeanwellCEOSell8,623$40.00$344,920.00View SEC Filing  
9/1/2016Clive MeanwellCEOSell1,377$40.00$55,080.00View SEC Filing  
8/24/2016Clive MeanwellCEOSell20,000$40.00$800,000.00View SEC Filing  
7/11/2016Hiroaki ShigetaDirectorSell3,849$38.50$148,186.50View SEC Filing  
6/10/2016Christopher T CoxEVPBuy45,985$37.90$1,742,831.50View SEC Filing  
6/7/2016Christopher T CoxEVPBuy53,340$37.55$2,002,917.00View SEC Filing  
5/24/2016Melvin K SpigelmanDirectorSell15,000$37.00$555,000.00View SEC Filing  
5/16/2016Clive MeanwellCEOSell10,000$35.00$350,000.00View SEC Filing  
5/16/2016William CrouseDirectorSell15,000$35.15$527,250.00View SEC Filing  
5/13/2016Elizabeth H S WyattDirectorSell15,000$34.07$511,050.00View SEC Filing  
5/12/2016Fredric N EshelmanDirectorBuy300,000$33.68$10,104,000.00View SEC Filing  
3/7/2016Armin M KesslerDirectorSell8,100$34.82$282,042.00View SEC Filing  
11/13/2015Robert G. SavageDirectorSell5,000$39.34$196,700.00View SEC Filing  
9/3/2015Glenn SblendorioCFOSell25,000$42.00$1,050,000.00View SEC Filing  
8/31/2015Clive MeanwellCEOSell49,998$39.36$1,967,921.28View SEC Filing  
8/31/2015Glenn SblendorioCFOSell114,495$39.75$4,551,176.25View SEC Filing  
8/31/2015Melvin K. SpigelmanDirectorSell20,000$40.50$810,000.00View SEC Filing  
8/31/2015William Bernard O'connorSVPSell35,451$40.00$1,418,040.00View SEC Filing  
7/1/2015Clive MeanwellCEOSell16,667$28.39$473,176.13View SEC Filing  
6/25/2015Glenn SblendorioCFOSell3,305$32.00$105,760.00View SEC Filing  
6/8/2015Hiroaki ShigetaDirectorSell7,500$28.99$217,425.00View SEC Filing  
5/20/2015Robert G SavageDirectorSell15,000$26.78$401,700.00View SEC Filing  
4/16/2015William Bernard O'connorSVPSell1,281$30.00$38,430.00View SEC Filing  
4/1/2015Clive MeanwellCEOSell16,667$27.58$459,675.86View SEC Filing  
3/30/2015Elizabeth H S WyattDirectorSell20,000$28.08$561,600.00View SEC Filing  
3/23/2015Clive MeanwellCEOSell16,667$30.62$510,343.54View SEC Filing  
3/23/2015Glenn SblendorioCFOSell34,773$30.78$1,070,312.94View SEC Filing  
3/2/2015William Bernard O'connorSVPSell2,988$28.78$85,994.64View SEC Filing  
3/3/2014William Bernard O'connorSVPSell2,968$30.31$89,960.08View SEC Filing  
1/21/2014Paul Michael AntinoriVPSell37,883$38.02$1,440,311.66View SEC Filing  
1/15/2014William Bernard O'connorSVPSell4,427$39.15$173,317.05View SEC Filing  
1/10/2014William Bernard O'connorSVPSell72,384$40.00$2,895,360.00View SEC Filing  
1/7/2014Clive MeanwellCEOSell27,929$38.13$1,064,932.77View SEC Filing  
1/3/2014Clive MeanwellCEOSell57,516$38.16$2,194,810.56View SEC Filing  
12/9/2013William CrouseDirectorSell12,500$38.00$475,000.00View SEC Filing  
12/5/2013Glenn SblendorioCFOSell8,516$38.50$327,866.00View SEC Filing  
12/2/2013Clive MeanwellCEOSell10,000$36.58$365,800.00View SEC Filing  
11/26/2013Clive MeanwellCEOSell135,000$36.70$4,954,500.00View SEC Filing  
10/23/2013William Bernard O'connorSVPSell6,354$35.00$222,390.00View SEC Filing  
9/13/2013Paul Michael AntinoriVPSell73,500$34.50$2,535,750.00View SEC Filing  
9/3/2013Clive MeanwellCEOSell7,500$31.85$238,875.00View SEC Filing  
8/1/2013Clive MeanwellCEOSell7,500$31.26$234,450.00View SEC Filing  
7/8/2013Paul Michael AntinoriVPSell36,000$33.00$1,188,000.00View SEC Filing  
7/1/2013Clive MeanwellCEOSell7,500$31.25$234,375.00View SEC Filing  
6/11/2013Paul Michael AntinoriVPSell109,973$33.29$3,661,001.17View SEC Filing  
5/29/2013Armin M KesslerDirectorSell8,750$33.05$289,187.50View SEC Filing  
5/10/2013Glenn SblendorioCFOSell2,709$37.00$100,233.00View SEC Filing  
5/9/2013Paul Michael AntinoriVPSell35,000$34.90$1,221,500.00View SEC Filing  
5/9/2013William Bernard O'connorSVPSell29,654$35.00$1,037,890.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for The Medicines Company (NASDAQ:MDCO)
Latest Headlines for The Medicines Company (NASDAQ:MDCO)
Source:
DateHeadline
americanbankingnews.com logoThe Medicines Company (MDCO) Coverage Initiated at CIBC
www.americanbankingnews.com - May 23 at 2:30 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for The Medicines Company's Q2 2017 Earnings (MDCO)
www.americanbankingnews.com - May 23 at 7:18 AM
finance.yahoo.com logoETFs with exposure to The Medicines Co. : May 22, 2017
finance.yahoo.com - May 22 at 5:50 PM
americanbankingnews.com logoThe Medicines Company (MDCO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 22 at 12:25 PM
americanbankingnews.com logoThe Medicines Company (MDCO) Coverage Initiated at Oppenheimer Holdings Inc.
www.americanbankingnews.com - May 22 at 11:30 AM
americanbankingnews.com logoThe Medicines Company (MDCO) Cut to Strong Sell at ValuEngine
www.americanbankingnews.com - May 21 at 8:38 PM
finance.yahoo.com logoThis Fund’s Picks Gained 200% In A Year And Why No One Knows About It
finance.yahoo.com - May 16 at 6:17 PM
finance.yahoo.com logoETFs with exposure to The Medicines Co. : May 11, 2017
finance.yahoo.com - May 11 at 6:58 PM
seekingalpha.com logoThe Medicines Company Gets The Go-Ahead On Novel Cardiovascular Drug
seekingalpha.com - May 9 at 6:11 PM
finance.yahoo.com logoThe Medicines Co. :MDCO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 11:51 AM
americanbankingnews.com logoThe Medicines Company (MDCO) Expected to Announce Earnings of -$1.24 Per Share
www.americanbankingnews.com - May 9 at 8:10 AM
zacks.com logoDo Options Traders Know Something About Medicines Company (MDCO) Stock We Don't?
www.zacks.com - May 8 at 11:59 AM
finance.yahoo.com logoDo Options Traders Know Something About Medicines Company (MDCO) Stock We Don't?
finance.yahoo.com - May 8 at 11:59 AM
americanbankingnews.com logoThe Medicines Company (MDCO) Short Interest Up 3.6% in April
www.americanbankingnews.com - May 7 at 11:22 AM
finance.yahoo.com logoThe Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference - Yahoo Finance
finance.yahoo.com - May 4 at 6:33 PM
businesswire.com logoThe Medicines Company to Participate in the Bank of America ... - Business Wire (press release)
www.businesswire.com - May 4 at 6:33 PM
finance.yahoo.com logoThe Medicines Company to Participate in the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 4 at 11:42 AM
seekingalpha.com logoAlnylam Teams Up With The Medicines Company To Upset PCSK9 Antibody Market
seekingalpha.com - May 1 at 5:29 PM
americanbankingnews.com logoThe Medicines Company to Post Q2 2017 Earnings of ($1.40) Per Share, Jefferies Group Forecasts (MDCO)
www.americanbankingnews.com - May 1 at 7:55 AM
americanbankingnews.com logoThe Medicines Company (MDCO) Receives News Impact Score of 0.09
www.americanbankingnews.com - April 29 at 11:33 PM
streetinsider.com logoMedicines Company (MDCO), Alnylam (ALNY) Announce Agreement with FDA on Phase III Clinical Program for Inclisiran - StreetInsider.com
www.streetinsider.com - April 29 at 12:25 AM
finance.yahoo.com logoThe Medicines Company (MDCO) Q1 Loss Wider Than Expected - Yahoo Finance
finance.yahoo.com - April 29 at 12:25 AM
americanbankingnews.com logoLeerink Swann Comments on The Medicines Company's Q2 2017 Earnings (MDCO)
www.americanbankingnews.com - April 28 at 9:40 AM
finance.yahoo.com logoEdited Transcript of MDCO earnings conference call or presentation 26-Apr-17 12:30pm GMT
finance.yahoo.com - April 27 at 7:02 PM
zacks.com logoThe Medicines Company (MDCO) Q1 Loss Wider Than Expected
www.zacks.com - April 27 at 9:29 AM
finance.yahoo.com logoBlog Coverage Medicines Co. Reaches Agreement with FDA for the Phase III Trial for Inclisiran
finance.yahoo.com - April 27 at 9:28 AM
seekingalpha.com logoThe Medicines (MDCO) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 6:53 PM
streetinsider.com logoMedicines Company (MDCO), Alnylam (ALNY) Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
www.streetinsider.com - April 26 at 6:53 PM
finance.yahoo.com logoThe Medicines Company Reports First-Quarter 2017 Financial Results
finance.yahoo.com - April 26 at 6:53 PM
finance.yahoo.com logoMedicines Co. reports 1Q loss
finance.yahoo.com - April 26 at 6:53 PM
finance.yahoo.com logoThe Medicines Co. – Value Analysis (NASDAQ:MDCO) : April 26, 2017
finance.yahoo.com - April 26 at 6:53 PM
americanbankingnews.com logoThe Medicines Company (MDCO) Releases Earnings Results, Misses Expectations By $0.21 EPS
www.americanbankingnews.com - April 26 at 6:30 PM
seekingalpha.com logoThe Medicines reports Q1 results
seekingalpha.com - April 26 at 10:28 AM
seekingalpha.com logoMedicines beats by $0.22, misses on revenue
seekingalpha.com - April 26 at 7:23 AM
finance.yahoo.com logoThe Medicines Co. breached its 50 day moving average in a Bearish Manner : MDCO-US : April 25, 2017
finance.yahoo.com - April 25 at 5:48 PM
americanbankingnews.com logoThe Medicines Company (MDCO) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 25 at 12:33 PM
finance.yahoo.com logoDrug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More
finance.yahoo.com - April 25 at 8:33 AM
feeds.benzinga.com logoEditas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting
feeds.benzinga.com - April 24 at 3:27 PM
americanbankingnews.com logoThe Medicines Company (MDCO) Getting Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 22 at 12:38 AM
americanbankingnews.com logoThe Medicines Company Expected to Earn FY2019 Earnings of ($3.03) Per Share (MDCO)
www.americanbankingnews.com - April 21 at 5:34 PM
businesswire.com logoThe Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational ... - Business Wire (press release)
www.businesswire.com - April 19 at 11:33 PM
streetinsider.com logoThe Medicines Company (MDCO) PT Raised to $61 at Cowen Following Positive Survey on Inclisiran - StreetInsider.com
www.streetinsider.com - April 19 at 11:33 PM
americanbankingnews.com logoThe Medicines Company (MDCO) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - April 19 at 6:15 PM
streetinsider.com logoMedicines Co. (MDCO) to Present Data at ECCMID
www.streetinsider.com - April 19 at 10:39 AM
americanbankingnews.com logoThe Medicines Company (MDCO) Getting Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 18 at 5:44 PM
americanbankingnews.com logo-$1.13 EPS Expected for The Medicines Company (MDCO) This Quarter
www.americanbankingnews.com - April 18 at 9:42 AM
americanbankingnews.com logoThe Medicines Company's (MDCO) "Buy" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - April 18 at 7:40 AM
finance.yahoo.com logoThe Medicines Company to Present Data at ECCMID 2017 on Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam
finance.yahoo.com - April 17 at 10:18 AM
americanbankingnews.com logoThe Medicines Company (MDCO) Receiving Positive Media Coverage, Analysis Finds
www.americanbankingnews.com - April 15 at 10:07 AM
finance.yahoo.com logoThe Medicines Company to Announce First-Quarter 2017 Financial Results on ...
finance.yahoo.com - April 13 at 9:04 AM

Social

Chart

The Medicines Company (MDCO) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff